Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based full-service contract manufacturer (CMO) of mammalian and microbial biologics, Cytovance Biologics is extending its manufacturing agreement with a clinical stage biopharmaceutical firm Precision Biologics for the development of monoclonal antibody candidate ensituximab or NEO-102.
Subscribe to our email newsletter
Currently, Precision is advancing its clinical trials with NEO-102, which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers.
As part of the deal, Cytovance will offer Precision technology transfer and additional cGMP manufacturing services of NEO-102 in support of its ongoing Phase II clinical trials.
Precision Biologics COO Albine Martin said with this agreement, the company is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance.
"Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers," Martin said.
Cytovance Biologics president and chief executive officer Darren Head said, "Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics.
Precision is focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer.
Cytovance specializes in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation.
Apart from its cGMP manufacturing services, the company provides process development, cGMP cell banking and support services from its Oklahoma City facilities.